SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (472)5/30/2003 2:05:44 PM
From: Mike McFarlandRespond to of 1336
 
Tripped on Xenoport one too many times...fwiw...

Since its inception in 1999, XenoPort has raised over
$90 million in private venture funding. XenoPort's
investors include Alejandro Zaffaroni, Arch Ventures,
CMEA Ventures, Frazier & Co., HBM BioVentures AG,
Lilly BioVentures, Lombard Odier & Cie, Lotus
BioScience Ventures, Novartis BioVentures Ltd.,
Orbimed Advisors, Skyline Ventures, The Invus Group,
and Venrock Associates.

That may actually be the Novartis Venture Fund
venturefund.novartis.com

GlaxoSmithKline has a venture fund called SR One

Well for crying out loud, here is an article from
about a year ago at Signals:
signalsmag.com



To: Mike McFarland who wrote (472)5/30/2003 4:30:26 PM
From: nigel batesRead Replies (1) | Respond to of 1336
 
Hi Mike.
No idea what's with RIGL. I too sold out at a similar level.
I'm similarly bemused with RNAI, and the new cash is in the bank there.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News